Cantor Fitzgerald analyst Louise Chen raised the firm’s price target on Eli Lilly to $485 from $432 and keeps an Overweight rating on the shares. The firm remains positive on the stock following the "mixed" Q1 report, the analyst tells investors in a research note. Eli Lilly reported positive SURMOUNT-2 data for tirzepatide in obesity, the firm notes.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Eli Lilly price target raised to $420 from $400 at Credit Suisse
- Eli Lilly price target raised to $430 from $400 at JPMorgan
- Eli Lilly price target raised to $447 from $438 at UBS
- Eli Lilly price target raised to $440 from $375 at Wells Fargo
- Investors Cheer Eli Lilly’s Obesity Drug Update, Ignore Weak Earnings
